The first site in Asia to conduct trials with the Medtronic Micra TPS and Attain Stability Quad left heart lead

KUALA LUMPUR, 22 JANUARY 2018 – Institut Jantung Negara (IJN) today announced that it is the first hospital in Asia to conduct first in man trials with Medtronic on the Micra® Transcatheter Pacing System (TPS) IJN also announced that it is the first hospital in Asia to  implant the investigational Attain Stability™ Quad MRI SureScan™ left heart lead. IJN has been collaborating with Medtronic for more than 10 years now, and continues to offer the broadest range of innovative medical technology for interventional and surgical treatment of cardiovascular diseases to its patients.

“Our collaboration with Medtronic has enabled us to further innovate in cardiac medical technology and to be seen as thought leaders in the industry. Both IJN and Medtronic have the same objectives, which is to ensure patients receive only the best cardiac medical solutions and care from us. We want to continue to be a training center and Center of Excellence embracing the latest cardiac medical technology not only in the Asia Pacific region, but also worldwide. Together we will strive to offer products and services of the highest quality that deliver the best clinical and economic value to cardiac patients in Malaysia,” said Dato’ Seri Dr. Mohd Azhari Yakub, CEO, Institut Jantung Negara (IJN).

Offering the world’s smallest pacemaker for patients with bradycardia, the Micra® Transcatheter Pacing System is a new type of heart device, which provides patients with the most advanced pacing technology at one-tenth the size of a traditional pacemaker,   via a minimally invasive approach. During the implant procedure, it is attached to the heart with small tines and delivers electrical impulses that pace the heart through an electrode at the end of the device.

Unlike traditional pacemakers, the Micra TPS does not require leads or a surgical “pocket” under the skin, so potential sources of complications related to such leads and pocket are eliminated – as are any visible signs of the device.

The first-in-man trial procedure for the Micra® Transcatheter Pacing System was performed by IJN on 18 March 2014. To date, IJN has implanted more than 200 Micra® Transcatheter Pacing Systems since its commercial launch in 2015. Progressing from being in the first in man trial, IJN is involved in training and education of this novel technology. This center is the first Micra training center outside of Minnesota, USA. The Center of Excellence has trained 80 physicians from Australia, Korea, Hong Kong, Singapore, Thailand, India, Philippines and Malaysia on this advanced pacing technology since December 2015.  IJN has also been involved in other early feasibility studies of investigational technologies.

The Attain Stability Quad lead features novel, active-fixation technology that is designed for precise lead placement and stability, and can be paired with Medtronic quadripolar cardiac resynchronisation therapy defibrillators (CRT-D) and pacemakers (CRT-P). This new lead provides an option for left ventricular lead placement that can meet the needs of patients with various anatomies.

The first trial procedure for the Attain Stability Quad in Asia was performed by IJN on 24 August 2017]. IJN is the first site outside of the United States to initiate the clinical study.

IJN has trained more than 200 physicians across the Asia Pacific region with countries such as Japan, Korea, Hong Kong, Australia, New Zealand, Taiwan, India, Scotland and South East Asia for cardiac resynchronisation therapy defibrillators (CRT-D) and pacemakers (CRT-P).“We are committed to working with interventional cardiologists and cardiac surgeons to deliver solutions that address patient needs with the innovative technology, safety, and performance profile they expect from Medtronic. Together with IJN, our partnership will use the power of technology to improve the lives of patients with cardiovascular diseases in Malaysia. More importantly, we are excited to work with IJN to deliver our latest products and services so as to reach more physicians and patients, and to alleviate pain, restore health, and extend life,” said Cheng Chee Hui, Country Director, Medtronic, Malaysia.

IJN is committed to serving and providing our community with the most advanced cardiac technology, and its thought leadership in providing the best cardiac medical products and solutions is in line with its mission to have its patients needs first with safest and highest quality care.

About IJN


Institut Jantung Negara (IJN) was set up in 1992 and is dedicated to the management and treatment of heart diseases by providing cardiology, paediatric cardiology and cardiothoracic surgery services for adults and children.

Today, IJN is reckoned to be among the best medical centres for cardiovascular and thoracic care in Malaysia and the region. IJN has kept abreast with the latest medical advances, from handling a simple hole in the heart surgery to heart and lungs transplantations.

With a strong commitment to be a global heart care centre of excellence, IJN has paved the way by creating many “firsts” for cardiovascular and thoracic care in the country, namely:


  1. 1st in SEA to introduce AXXESS Stent to treat bifurcation leasions
  2. 1st in Asia to introduce Renal Denervation – a radio frequency ablation procedure to treat patients with resistant hypertension
  3. 1st in the SEA to implant Bio resorbable Vascular Scaffold – a new stenting device
  4. 1st in the country to implant the Watchman device to reduce the risk of stroke in patient with AF
  5. Introduced HeartMate II – a new mechanical heart assist device as a bridge to transplantation in 2010
  6. 1st in Malaysia to perform Transcatheter Aortic Valve Implantation (TAVI)
  7. 1st in Malaysia to perform minimally invasive lobectomy for lung disease
  8. 1st in the country to perform minimally invasive procedure to repair congenital chest deformity called “Pectus Excavatum” and “Pectus Carinatum”
  9. 1st in Malaysia to perform a double heart transplantation (redo) within 24 hours
  10. 1st to perform key hole (endoscopic) surgery to treat lone atrial fibrillation in Asia and Australasia in 2006
  11. 1st to perform single and double lungs transplant
  12. 1st to perform the implantation of an Implantable Ventricular Assist Device (IVAD).
  13. 1st medical institute in the country and the Southeast Asean region to perform coronary bypass surgeries and complex thymectomy procedures on conscious or ‘awake’ patients without general anesthesia.
  14. 1st in Malaysia to perform bone marrow stem cell transplantation in patients suffering from severe ischemic heart disease with no other treatment options.
  15. 1st medical institute to conduct a homograft procurement to facilitate heart transplant.
  16. 1st medical institute in the country to perform a heart transplant.
  17. One of the first in the region to perform detailed mapping for complex arrhythmia.
  18. 1st medical institute in the world to Implant a Bio-absorbable Pulmonary Valve Conduit
  19. 1st medical institute in Malaysia to carry out the complete replacement of the aorta.

About Medtronic

Medtronic plc (, headquartered in Dublin, Ireland, is among the world’s largest medical technology, services and solutions companies – alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 84,000 people worldwide, serving physicians, hospitals and patients in approximately 160 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.



This release is issued by the Corporate Communications Department of Institut Jantung Negara. 

For further enquiries please contact:

Ms. Aina Jamil at 03-2600 6316, 012-3891800,

Ms Izrinda Badrolhisham at 03-2600 6308, 018-378 8896

Mr. David Cleghorn at +61438494649 / +6590177896




Book an Appointment